Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Nodin, Björn ^a   Hedner, Charlotta ^a,b   Uhlén, Mathias ^c,d   Jirström, Karin ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b University and Regional Laboratories Region Skåne ^*  (Sweden)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Epithelial ovarian cancer; Immunohistochemistry; Prognosis; SATB1

Indexed keywords

BINDING PROTEIN; CHECKPOINT KINASE 1; MINICHROMOSOME MAINTENANCE PROTEIN 3; SPECIAL AT RICH SEQUENCE BINDING PROTEIN1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; UTERINE TUBE;

EID: 84866279361     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-24     Document Type: Article

References (22)

1. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T, Genes Dev 2000 14 5 521 535 10716941
2. SATB1 targets chromatin remodelling to regulate genes over long distances. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T, Nature 2002 419 6907 641 645 10.1038/nature01084 12374985
3. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T, Nature 2008 452 7184 187 193 10.1038/nature06781 18337816
4. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, Liu K, Wu K, Tong Q, APMIS 2010 118 11 855 863 10.1111/j.1600-0463.2010.02673.x 20955458
5. SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Lu X, Cheng C, Zhu S, Yang Y, Zheng L, Wang G, Shu X, Wu K, Liu K, Tong Q, Oncol Rep 2010 24 4 981 987 20811679
6. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, He J, Han P, Tian D, Liver international: official journal of the International Association for the Study of the Liver 2012 32 7 1064 1078 10.1111/j.1478-3231.2012.02815.x
7. Upregulation of SATB1 is associated with the development and progression of glioma. Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC, J Transl Med 2012 10 1 149 10.1186/1479-5876-10-149 22839214
8. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Nodin B, Johannesson H, Wangefjord S, DP OC, Ericson-Lindquist K, Uhlen M, Jirstrom K, Eberhard J, Diagn Pathol 2012 7 1 115 10.1186/1746-1596-7-115 22935204
9. Correlation of SATB1 overexpression with the progression of human rectal cancer. Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, Zhan L, Li Y, Zhou ZG, Sun XF, Int J Colorectal Dis 2012 27 2 143 150 10.1007/s00384-011-1302-9 21870058
10. AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma. Xiang J, Zhou L, Li S, Xi X, Zhang J, Wang Y, Yang Y, Liu X, Wan X, Oncology letters 2012 3 4 865 870 22741008
11. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, Jirstrom K, J Ovarian Res 2010 3 14 10.1186/1757-2215-3-14 20565760
12. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al. J Transl Med 2010 8 78 10.1186/1479-5876-8-78 20727170
13. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K, Translational oncology 2011 4 4 212 221 21804916
14. Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer. Nodin B, Fridberg M, Uhlen M, Jirstrom K, J Ovarian Res 2012 5 1 6 10.1186/1757-2215-5-6 22284433
15. The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. Kolkova Z, Casslen V, Henic E, Ahmadi S, Ehinger A, Jirstrom K, Casslen B, J Ovarian Res 2012 5 9 10.1186/1757-2215-5- 9 22424333
16. Histopathologic grading of ovarian carcinoma: a review and proposal. Silverberg SG, Int J Gynecol Pathol 2000 19 1 7 15 10.1097/00004347-200001000- 00003 10638449
17. REporting recommendations for tumour MARKer prognostic studies (REMARK). McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Eur J Cancer 2005 41 12 1690 1696 10.1016/j.ejca.2005.03.032 16043346
18. Genome organizing function of SATB1 in tumor progression. Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev V, Kohwi Y, Seminars in cancer biology 2012 Jul 4 [Epub ahead of print]
19. The cell of origin of ovarian epithelial tumours. Dubeau L, Lancet Oncol 2008 9 12 1191 1197 10.1016/S1470-2045(08)70308-5 19038766
20. The mRNA expression of SATB1 and SATB2 in human breast cancer. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K, Cancer Cell Int 2009 9 18 10.1186/1475-2867-9-18 19642980
21. SATB1 gene expression and breast cancer prognosis. Hanker LC, Karn T, Mavrova-Risteska L, Ruckhaberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I, Breast 2011 20 4 309 313 10.1016/j.breast.2010.10.002 20980149
22. Early events in the pathogenesis of epithelial ovarian cancer. Landen CN Jr, Birrer MJ, Sood AK, J Clin Oncol 2008 26 6 995 1005 10.1200/JCO.2006.07.9970 18195328